Explore how real-time data and open-source information can revolutionize medicine in this 47-minute talk by Patrick Vallance, President of Research and Development at GlaxoSmithKline. Delve into critical questions surrounding data-driven medicine, examining case studies like Blous syndrome and lung disease. Learn about open targets, digital descriptions, and the process of identifying molecules for drug development. Discover the potential of new therapeutics, open innovation, and continuous data collection in improving healthcare outcomes. Investigate the importance of clinical trials, primary and secondary care, and social listening in understanding real-world effects of treatments. Gain insights into the transformation of drug discovery and the future of personalized medicine through data-driven approaches.
Overview
Syllabus
Intro
Why is this important
The 4 critical questions
Blous syndrome
Lung disease
Open targets
Identifying molecules
Digital description
Example
Drug molecules
New therapeutics
Open innovation
Data collection
Continuous measurements
Questions to ask
What happens in the real world
Two different areas
Clinical trials
Primary and secondary care
Social listening
Summary
Taught by
The Royal Institution
